Business Context and Reporting Period
This Form 8-K is a current report filed by Leap Therapeutics, Inc. (noted as "CYPHERPUNK TECHNOLOGIES INC." in request metadata) on February 1, 2019. The registrant is a Delaware corporation headquartered in Cambridge, MA, and has elected to be treated as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves to announce a corporate event rather than present periodic financial statements.
Material Changes
- Public Offering: On February 1, 2019, the Company priced a previously announced public offering of its common stock and warrants to purchase common stock.
- Disclosure: The full details of the offering are contained in a press release filed as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard disclosure of the offering event. The text refers readers to the attached press release for further details regarding the transaction.
Investor Verification Checklist
- Verify the specific terms of the common stock and warrant offering in Exhibit 99.1 (Press Release dated February 1, 2019).
- Confirm the final offering price and total capital raised, as these figures are not included in the 8-K body text.
- Review the Company's status as an emerging growth company and any associated election regarding extended transition periods for accounting standards.